Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a disease with a widely varying prognosis. The majority of patients survive about 3 years, but a significant number survive for 10 years or more, leading to problems in clinical trial design. OBJECTIVE: To demonstrate that simple clinical variables can be used to construct a robust predictive model for survival, and to assess the effect of a known treatment within this model. METHODS: We carried out a retrospective multivariate modelling of a database of 841 patients with ALS seen over a 10-year period in a specialist motor neuron disorders clinic. The use of riluzole was tested as a prognostic factor within the model. RESULTS: A prognostic score generated from one cohort of patients predicted survival for a second cohort of patients (r(2) = 0.78). Prognostic variables included site of onset, age of onset, time from symptom onset to diagnosis, and El Escorial category at presentation. Riluzole therapy was an independently significant prognostic factor (relative risk of death 0.48, P < 0.0001, model chi(2) 297, P < 0.0001). CONCLUSIONS: Clinical databases can be used to generate multivariate prognostic models in ALS. Such models could be used to predict survival, to improve criteria for matching of patients in future clinical trials, and to test the impact of interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433 · cited 1×
“The 1994 El Escorial classication was used because the study began before the updated classication had come into effect.(2,3) It was retrospectively applied to patients seen before publication, on the basis of their clinical ndings at our initial assessment.”
MethodIncidence and prevalence of ALS in Ireland, 1995–1997: A population-based study
Traynor, B. J., Codd, M. B., Corr, B., Forde, C., Frost, E., & Hardiman, O. (1999) · Neurology · doi:10.1212/wnl.52.3.504 · Cited by 292
Cited by
Prognostic factors in ALS: A critical review
Chiò, A., Logroscino, G., Hardiman, O., Swingler, R., Mitchell, D., Beghi, E., Traynor, B. G., & On Behalf of the Eurals Consortium (2009) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482960802566824 · Cited by 1,172
The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:, Andersen, P. M., Abrahams, S., Borasio, G. D., de Carvalho, M., Chio, A., Van Damme, P., Hardiman, O., Kollewe, K., Morrison, K. E., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03501.x · Cited by 1,117
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)
Miller, R., Mitchell, J., Lyon, M., & Moore, D. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001447 · Cited by 909
Miller, R. G., Jackson, C. E., Kasarskis, E. J., England, J. D., Forshew, D., Johnston, W., Kalra, S., Katz, J. S., Mitsumoto, H., Rosenfeld, J., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bc0141 · Cited by 807
Turner, M. R., Cagnin, A., Turkheimer, F. E., Miller, C. C. J., Shaw, C. E., Brooks, D. J., Leigh, P. N., & Banati, R. B. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.012 · Cited by 737
“Median survival (in a clinic setting) is 3–4 years from symptom onset (Turner et al., 2002), but can be more than 10 years for a small proportion of patients (Turner et al., 2003), reflecting the heterogeneous nature of the disease (Shinsuke at al., 2003).”
BackgroundSelf-citation
Metadata
- Authors
- Turner, M., Bakker, M., Sham, P., Shaw, C., Leigh, P., & Al-Chalabi, A.
- Venue
- Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders
- Publisher
- Informa UK Limited
- Published
- 2002-01
- Volume
- 3
- Issue
- 1
- Pages
- 15-21
- ISSN
- 1466-0822 (ISSN-L)
- OpenAlex
- W2251772006
- Cited by
- 97
- References
- 2
- FWCI
- 4.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. https://app.cochat.ai/papers/10.1080/146608202317576499
- The paper
- Turner, M., Bakker, M., Sham, P., Shaw, C., Leigh, P., & Al-Chalabi, A. (2002). Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders. https://doi.org/10.1080/146608202317576499
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.